BioCentury
ARTICLE | Company News

Codexis deal

September 28, 2015 7:00 AM UTC

Codexis will use its CodeEvolver platform to develop an enzyme for use in an undisclosed company’s preclinical therapeutic development program. Codexis said a proof-of-concept study is expected to be completed in about six months. If Codexis’ partner elects to continue the program, “enzyme evolution” is expected to last six to 12 months. ...